February 2012 | Oncology Live®

April 12, 2012

Elotuzumab demonstrated notable response rates as combination therapy in a phase II study of patients with relapsed or refractory multiple myeloma.

March 13, 2012

Approximately 7% of Americans are infected with oral human papillomavirus (HPV), and men are 3 times as likely to be infected as women.

March 13, 2012

An interview with Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, who has dedicated the past 30 years to helping patients with lung cancer.

March 12, 2012

Once injectable agents were proven to lower testosterone levels, they became the preferred treatment among patients and their treatment teams.

March 07, 2012

The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment.

March 06, 2012

A review of interesting presentations from ASH that will stimulate highly clinically relevant discussion regarding disease management within the realm of the hematologic malignancies.

March 02, 2012

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.

March 01, 2012

Bevacizumab has failed to demonstrate statistically significant improvements in OS for women with recurrent ovarian cancer in 2 recent clinical trials.

March 01, 2012

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

February 29, 2012

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

February 23, 2012

Two phase III clinical trials showed that nilotinib continues to demonstrate more favorable molecular response levels in patients with Ph CML than imatinib mesylate.

February 23, 2012

Patients who initially exhibit a response to a particular strategy may achieve substantial clinical benefit if the same or very similar agents are delivered after variably defined treatment-free intervals.